Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/37707
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ploumen, EH | - |
dc.contributor.author | Buiten, RA | - |
dc.contributor.author | Kok, MM | - |
dc.contributor.author | Doggen, CJM | - |
dc.contributor.author | Roguin, A | - |
dc.contributor.author | Jessurun, GAJ | - |
dc.contributor.author | Schotborgh, CE | - |
dc.contributor.author | Danse, PW | - |
dc.contributor.author | BENIT, Edouard | - |
dc.contributor.author | Aminian, A | - |
dc.contributor.author | van Houwelingen, KG | - |
dc.contributor.author | Stoel, MG | - |
dc.contributor.author | Scholte, M | - |
dc.contributor.author | Hartmanna, M | - |
dc.contributor.author | Linssen, GCM | - |
dc.contributor.author | Zocca, P | - |
dc.contributor.author | von Birgelen, C | - |
dc.date.accessioned | 2022-07-13T09:07:49Z | - |
dc.date.available | 2022-07-13T09:07:49Z | - |
dc.date.issued | 2021 | - |
dc.date.submitted | 2022-07-06T14:37:58Z | - |
dc.identifier.citation | International journal of cardiology (print), 325 , p. 37 -44 | - |
dc.identifier.uri | http://hdl.handle.net/1942/37707 | - |
dc.description.abstract | Background: Patients with diabetes have more extensive coronary disease, resulting in higher risks of adverse clinical events following stenting. In all-corner patients, contemporary DES have shown excellent safety and efficacy, but data on diabetic patients are scarce. Separately for the BIO-RESORT and BIONYX trials, we assessed the 2-year clinical outcomes of diabetic patients, treated with various contemporary drug-eluting stents (DES).Methods: We performed two prespecified secondary analyses of two randomized DES trials, which both stratified for diabetes. The main endpoint was target vessel failure (WI), a composite of cardiac death, target vessel myocardial infarction, or target vessel revascularization. Follow-up was finished before the COVID-19 pandemic.Results: In BIO-RESORT, 624/3514 (17.8%) had diabetes: 211 received Orsiro sirolimus-eluting stents (SES), 203 Synergy everolimus-eluting stents (EES), and 210 Resolute Integrity zotarolimus-eluting stents (RI-ZES). TVF did not differ between SES (10.2%) and EES (10.0%) versus RI-ZES (12.7%) (SES vs. RI-ZES HR:0.78, 95%-CI [0.44-1.40]; p = 0.40, EES vs. RI-ZES HR:0.79, 95%-CI [0.44-1.40]; p = 0.42). In BIONYX, 510/2488 (20.5%) patients had diabetes: 250 received SES and 260 Resolute Onyx zotarolimus-eluting stents (RO-ZES). There was no difference in TVF between SES (10.7%) versus RO-ZES (12.2%) (HR:0.88, 95%-CI [0.52-148]; p = 0.63).Conclusions: There was no difference in 2-year clinical outcome among patients with diabetes, who were treated with SES, or EES. versus RI-ZES. In addition there was no difference in clinical outcome in diabetic patients, who were treated with SES versus RO-ZES. These findings may be considered as a signal of safety and efficacy of the studied DES in patients with diabetes. (C) 2020 The Author(s). Published by Elsevier B.V. | - |
dc.description.sponsorship | The BIO-RESORT trial was equally funded by Biotronik, Boston Scientific, and Medtronic. The BIONYX trial was equally funded by Biotronik, and Medtronic. There was no external funding for performing the present study. | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER IRELAND LTD | - |
dc.rights | © 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). | - |
dc.subject.other | Percutaneous coronary intervention | - |
dc.subject.other | Randomized clinical trial | - |
dc.subject.other | Drug-eluting stents | - |
dc.subject.other | Diabetes mellitus | - |
dc.title | Treating diabetic all-comers with contemporary drug-eluting stents: Prespecified comparisons from the BIO-RESORT and the BIONYX randomized trials | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 44 | - |
dc.identifier.spage | 37 | - |
dc.identifier.volume | 325 | - |
local.bibliographicCitation.jcat | A1 | - |
local.publisher.place | ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.identifier.doi | 10.1016/j.ijcard.2020.10.051 | - |
dc.identifier.pmid | 33148427 | - |
dc.identifier.isi | 000623745900006 | - |
local.provider.type | Web of Science | - |
local.uhasselt.international | yes | - |
item.contributor | Ploumen, EH | - |
item.contributor | Buiten, RA | - |
item.contributor | Kok, MM | - |
item.contributor | Doggen, CJM | - |
item.contributor | Roguin, A | - |
item.contributor | Jessurun, GAJ | - |
item.contributor | Schotborgh, CE | - |
item.contributor | Danse, PW | - |
item.contributor | BENIT, Edouard | - |
item.contributor | Aminian, A | - |
item.contributor | van Houwelingen, KG | - |
item.contributor | Stoel, MG | - |
item.contributor | Scholte, M | - |
item.contributor | Hartmanna, M | - |
item.contributor | Linssen, GCM | - |
item.contributor | Zocca, P | - |
item.contributor | von Birgelen, C | - |
item.fullcitation | Ploumen, EH; Buiten, RA; Kok, MM; Doggen, CJM; Roguin, A; Jessurun, GAJ; Schotborgh, CE; Danse, PW; BENIT, Edouard; Aminian, A; van Houwelingen, KG; Stoel, MG; Scholte, M; Hartmanna, M; Linssen, GCM; Zocca, P & von Birgelen, C (2021) Treating diabetic all-comers with contemporary drug-eluting stents: Prespecified comparisons from the BIO-RESORT and the BIONYX randomized trials. In: International journal of cardiology (print), 325 , p. 37 -44. | - |
item.accessRights | Open Access | - |
item.fulltext | With Fulltext | - |
crisitem.journal.issn | 0167-5273 | - |
crisitem.journal.eissn | 1874-1754 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Treating diabetic all-comers with contemporary drug-eluting stents_ Prespecified comparisons from the BIO-RESORT and the BIONYX randomized trials.pdf | Published version | 1.64 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.